Workflow
【私募调研记录】同犇投资调研潮宏基、丸美生物等4只个股(附名单)
Zheng Quan Zhi Xing·2025-08-27 00:07

Group 1: Chao Hong Ji - The company has launched high-weight series products such as Zhenjin Zhenzuan and Fanhua to enhance customer price and will continue to focus on customer needs [1] - The online subsidiary's net profit increased by 70.64% year-on-year, promoting the integration of online and offline sales [1] - As of June, the number of stores reached 1,540, with 72 new stores added, and international expansion in Kuala Lumpur, Thailand, and Cambodia exceeded expectations [1] Group 2: Marubi Biological - The company has expanded its audience on Douyin through precise content delivery, leading to an increase in traffic [2] - The strategic investment in the second quarter is expected to convert into growth in the fourth quarter, with the brand "Lianhuo" entering a normal development phase [2] - The small gold needle series has improved customer purchase rates through synergy effects, and the company emphasizes both brand building and advertising investment [2] Group 3: Kangguan Technology - In the first half of 2025, the company achieved revenue of 6.935 billion, a year-on-year increase of 5.06%, and a net profit of 384 million [3] - Revenue from innovative display products increased by 39.16% year-on-year, driven by AI technology and successful overseas brand strategies [3] - The company announced a mid-term dividend of 3.60 yuan per 10 shares, accounting for over 65% of net profit [3] Group 4: Tianfu Communication - The company reported revenue of 2.456 billion in the first half of 2025, a year-on-year increase of 57.84%, and a net profit of 899 million, up 37.46% [4] - Growth in active products is attributed to increased deliveries of high-speed active products, with a strong demand for these products [4] - The company maintains high R&D investment and is expanding production capacity based on orders to ensure effective resource allocation [4]